Cargando…

Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation

PURPOSE: To validate caval subtraction two-dimensional (2D) phase-contrast magnetic resonance (MR) imaging measurements of total liver blood flow (TLBF) and hepatic arterial fraction in an animal model and evaluate consistency and reproducibility in humans. MATERIALS AND METHODS: Approval from the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chouhan, Manil D., Mookerjee, Rajeshwar P., Bainbridge, Alan, Walker-Samuel, Simon, Davies, Nathan, Halligan, Steve, Lythgoe, Mark F., Taylor, Stuart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radiological Society of North America 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015842/
https://www.ncbi.nlm.nih.gov/pubmed/27171018
http://dx.doi.org/10.1148/radiol.2016151832
_version_ 1782452493251248128
author Chouhan, Manil D.
Mookerjee, Rajeshwar P.
Bainbridge, Alan
Walker-Samuel, Simon
Davies, Nathan
Halligan, Steve
Lythgoe, Mark F.
Taylor, Stuart A.
author_facet Chouhan, Manil D.
Mookerjee, Rajeshwar P.
Bainbridge, Alan
Walker-Samuel, Simon
Davies, Nathan
Halligan, Steve
Lythgoe, Mark F.
Taylor, Stuart A.
author_sort Chouhan, Manil D.
collection PubMed
description PURPOSE: To validate caval subtraction two-dimensional (2D) phase-contrast magnetic resonance (MR) imaging measurements of total liver blood flow (TLBF) and hepatic arterial fraction in an animal model and evaluate consistency and reproducibility in humans. MATERIALS AND METHODS: Approval from the institutional ethical committee for animal care and research ethics was obtained. Fifteen Sprague-Dawley rats underwent 2D phase-contrast MR imaging of the portal vein (PV) and infrahepatic and suprahepatic inferior vena cava (IVC). TLBF and hepatic arterial flow were estimated by subtracting infrahepatic from suprahepatic IVC flow and PV flow from estimated TLBF, respectively. Direct PV transit-time ultrasonography (US) and fluorescent microsphere measurements of hepatic arterial fraction were the standards of reference. Thereafter, consistency of caval subtraction phase-contrast MR imaging–derived TLBF and hepatic arterial flow was assessed in 13 volunteers (mean age, 28.3 years ± 1.4) against directly measured phase-contrast MR imaging PV and proper hepatic arterial inflow; reproducibility was measured after 7 days. Bland-Altman analysis of agreement and coefficient of variation comparisons were undertaken. RESULTS: There was good agreement between PV flow measured with phase-contrast MR imaging and that measured with transit-time US (mean difference, −3.5 mL/min/100 g; 95% limits of agreement [LOA], ±61.3 mL/min/100 g). Hepatic arterial fraction obtained with caval subtraction agreed well with those with fluorescent microspheres (mean difference, 4.2%; 95% LOA, ±20.5%). Good consistency was demonstrated between TLBF in humans measured with caval subtraction and direct inflow phase-contrast MR imaging (mean difference, −1.3 mL/min/100 g; 95% LOA, ±23.1 mL/min/100 g). TLBF reproducibility at 7 days was similar between the two methods (95% LOA, ±31.6 mL/min/100 g vs ±29.6 mL/min/100 g). CONCLUSION: Caval subtraction phase-contrast MR imaging is a simple and clinically viable method for measuring TLBF and hepatic arterial flow. Online supplemental material is available for this article.
format Online
Article
Text
id pubmed-5015842
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Radiological Society of North America
record_format MEDLINE/PubMed
spelling pubmed-50158422017-04-26 Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation Chouhan, Manil D. Mookerjee, Rajeshwar P. Bainbridge, Alan Walker-Samuel, Simon Davies, Nathan Halligan, Steve Lythgoe, Mark F. Taylor, Stuart A. Radiology Original Research PURPOSE: To validate caval subtraction two-dimensional (2D) phase-contrast magnetic resonance (MR) imaging measurements of total liver blood flow (TLBF) and hepatic arterial fraction in an animal model and evaluate consistency and reproducibility in humans. MATERIALS AND METHODS: Approval from the institutional ethical committee for animal care and research ethics was obtained. Fifteen Sprague-Dawley rats underwent 2D phase-contrast MR imaging of the portal vein (PV) and infrahepatic and suprahepatic inferior vena cava (IVC). TLBF and hepatic arterial flow were estimated by subtracting infrahepatic from suprahepatic IVC flow and PV flow from estimated TLBF, respectively. Direct PV transit-time ultrasonography (US) and fluorescent microsphere measurements of hepatic arterial fraction were the standards of reference. Thereafter, consistency of caval subtraction phase-contrast MR imaging–derived TLBF and hepatic arterial flow was assessed in 13 volunteers (mean age, 28.3 years ± 1.4) against directly measured phase-contrast MR imaging PV and proper hepatic arterial inflow; reproducibility was measured after 7 days. Bland-Altman analysis of agreement and coefficient of variation comparisons were undertaken. RESULTS: There was good agreement between PV flow measured with phase-contrast MR imaging and that measured with transit-time US (mean difference, −3.5 mL/min/100 g; 95% limits of agreement [LOA], ±61.3 mL/min/100 g). Hepatic arterial fraction obtained with caval subtraction agreed well with those with fluorescent microspheres (mean difference, 4.2%; 95% LOA, ±20.5%). Good consistency was demonstrated between TLBF in humans measured with caval subtraction and direct inflow phase-contrast MR imaging (mean difference, −1.3 mL/min/100 g; 95% LOA, ±23.1 mL/min/100 g). TLBF reproducibility at 7 days was similar between the two methods (95% LOA, ±31.6 mL/min/100 g vs ±29.6 mL/min/100 g). CONCLUSION: Caval subtraction phase-contrast MR imaging is a simple and clinically viable method for measuring TLBF and hepatic arterial flow. Online supplemental material is available for this article. Radiological Society of North America 2016-09 2016-05-12 /pmc/articles/PMC5015842/ /pubmed/27171018 http://dx.doi.org/10.1148/radiol.2016151832 Text en http://creativecommons.org/licenses/by/4.0/ Published under a (http://creativecommons.org/licenses/by/4.0/) CC BY 4.0 license.
spellingShingle Original Research
Chouhan, Manil D.
Mookerjee, Rajeshwar P.
Bainbridge, Alan
Walker-Samuel, Simon
Davies, Nathan
Halligan, Steve
Lythgoe, Mark F.
Taylor, Stuart A.
Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation
title Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation
title_full Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation
title_fullStr Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation
title_full_unstemmed Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation
title_short Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation
title_sort use of caval subtraction 2d phase-contrast mr imaging to measure total liver and hepatic arterial blood flow: preclinical validation and initial clinical translation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015842/
https://www.ncbi.nlm.nih.gov/pubmed/27171018
http://dx.doi.org/10.1148/radiol.2016151832
work_keys_str_mv AT chouhanmanild useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT mookerjeerajeshwarp useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT bainbridgealan useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT walkersamuelsimon useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT daviesnathan useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT halligansteve useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT lythgoemarkf useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation
AT taylorstuarta useofcavalsubtraction2dphasecontrastmrimagingtomeasuretotalliverandhepaticarterialbloodflowpreclinicalvalidationandinitialclinicaltranslation